255 related articles for article (PubMed ID: 15146374)
21. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Betteridge DJ; Gibson JM
Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
23. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
24. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
[TBL] [Abstract][Full Text] [Related]
25. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
[TBL] [Abstract][Full Text] [Related]
26. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes.
Rizzo M; Berneis K; Altinova AE; Toruner FB; Akturk M; Ayvaz G; Rini GB; Spinas GA; Arslan M
Diabet Med; 2008 Dec; 25(12):1406-11. PubMed ID: 19046238
[TBL] [Abstract][Full Text] [Related]
27. [Cerivastatin-a new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor: effect of 0,2 mg dose in patients with primary hyperlipidemias].
Solov'eva EIu; Rozhkova TA; Tvorogova MG; Kukharchuk VV
Ter Arkh; 1999; 71(8):30-4. PubMed ID: 10515032
[TBL] [Abstract][Full Text] [Related]
28. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
[TBL] [Abstract][Full Text] [Related]
29. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
30. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study.
März W; Scharnagl H; Winkler K; Tiran A; Nauck M; Boehm BO; Winkelmann BR
Circulation; 2004 Nov; 110(19):3068-74. PubMed ID: 15505088
[TBL] [Abstract][Full Text] [Related]
31. Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control.
Aguilar-Salinas CA; Arita Melzer O; Sauque Reyna L; Lopez A; Velasco Perez ML; Guillen LE; Gomez Perez FJ; Rull Rodrigo JA
Isr Med Assoc J; 2001 Feb; 3(2):137-43. PubMed ID: 11344825
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
35. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.
Winkler K; Abletshauser C; Hoffmann MM; Friedrich I; Baumstark MW; Wieland H; März W
J Clin Endocrinol Metab; 2002 Dec; 87(12):5485-90. PubMed ID: 12466341
[TBL] [Abstract][Full Text] [Related]
36. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
[TBL] [Abstract][Full Text] [Related]
37. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
[TBL] [Abstract][Full Text] [Related]
38. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Bleske BE; Nicklas JM; Bard RL; Brook RD; Gurbel PA; Bliden KP; Rajagopalan S; Pitt B
J Am Coll Cardiol; 2006 Jan; 47(2):338-41. PubMed ID: 16412857
[TBL] [Abstract][Full Text] [Related]
39. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
40. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
März W; Scharnagl H; Abletshauser C; Hoffmann MM; Berg A; Keul J; Wieland H; Baumstark MW
Circulation; 2001 Apr; 103(15):1942-8. PubMed ID: 11306521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
